- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06249529
Airway Bypass - Safety and Feasibility Study (AIRWAY)
February 7, 2024 updated by: Zoar Engelman
Airway Bypass System - Safety and Feasibility Study A SINGLE-CENTER, PROSPECTIVE, SINGLE ARM STUDY TO EVALUATE THE SAFETY AND FEASIBILITY OF THE AIRWAY BYPASS SYSTEM
The objective of this study is to evaluate its safety and feasibility of the Airway Bypass Stent System in patients with severe emphysema.
The study will collect clinical data through 12 months to assess procedural and device safety.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tbilisi, Georgia
- Recruiting
- Israeli-Georgian Medical Research Clinic HEALTHYCORE
-
Contact:
- Tornike Jashi, MD
- Phone Number: 995595919096
- Email: jashitornike@gmail.com
-
Principal Investigator:
- David Tchkonia, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient between 50 to 80 years old.
- High Resolution CT scan indicates severe emphysema.
- Patient has post- bronchodilator FEV1 less than or equal to 50% of predicted.
- Total Lung Capacity >100% of predicted.
- Residual volume ≥225 % of predicted.
- RV/TLC >0.69
- Patient has marked dyspnea scoring >2 on mMRC scale of 0-4.
- Patient has stopped smoking for a minimum of 8 weeks prior to entering the study, as confirmed by COHb ≤2.5%.
- Patient read, understood, and signed the Informed Consent form.
- Subject has completed a pulmonary rehab within the last year and/or performs regular physical activity.
Exclusion Criteria:
- Patient has clinically significant sputum production.
- Patient has a change in FEV1 >20% post-bronchodilator.
- Patient has a history of recurrent clinically significant respiratory infection, defined as with more than 3 hospital stays in the past 12 months.
- Patient has uncontrolled pulmonary hypertension defined by right ventricular pressure >50mmHg and/or evidenced by echocardiogram.
- Patient has an inability to walk less than 140 meters (150 yards) or greater than 450 meters in 6 minutes.
- Patient has evidence of any other disease that may compromise survival such as lung cancer, renal failure, any other investigator identified diseases.
- Patient has an inability to tolerate bronchoscopy under anesthesia.
Any contraindication to bronchoscopy procedure, including but not limited to:
- Untreatable life-threatening arrhythmias
- Inability to adequately oxygenate the patient during the procedure
- Acute respiratory failure with hypercapnia
- Myocardial infarction within 6 months
- Previously diagnosed high-grade tracheal obstruction
- Uncorrectable coagulopathy
- Patient has clinically significant bronchiectasis.
- Patient has giant bullae >1/3 lung volume.
- Patient has had previous LVR surgery, lung transplant or lobectomy, or still has ELVR devices or other device to treat COPD in either lung.
- Patient has been involved in other clinical studies within 30 days prior to this study.
- Patient is taking >20mg prednisone (or similar steroid) daily.
- Patient on antiplatelet agent (e.g., clopidogrel) or anticoagulant therapy (e.g., heparin or coumadin) or has not been weaned off prior to procedure.
- Patient has any other disease that would interfere with completion of study, follow up assessments or that would adversely affect outcomes.
- A known allergy to nitinol.
- Patient with uncontrolled diabetes as well as overweight patient (BMI >35 kg/m2).
- Cancer needing chemotherapy in the past two years.
- Patient with pleural effusion and/or pneumothorax.
- Patient with a disease history of asthma, cystic fibrosis, interstitial lung disease (ILD), active tuberculosis.
- Patient with exacerbation of chronic obstructive pulmonary disease (COPD) within the last year which defined as: An acute event with the need of antibiotic treatment or hospitalization.
- Subject has severe gas exchange abnormalities as defined by: PaCO2 >55 mmHg, PaO2 <45 mmHg on room air.
- Patient with acute ischemic heart disease, with proven pulmonary hypertension (SPAP >45 mmHg) in echocardiography and/or need for double platelet aggregation inhibition.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interventional
Patients in the interventional arm will receive implant of one or more airway bypass devices.
|
Bypass stent(s) are implanted to allow air trapped in the parenchyma to escape
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: 12 Months
|
including but not limited to device-related blood vessel perforation, pneumothorax, COPD exacerbation, device migration, device removal, rehospitalization.
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Implant Success
Time Frame: 0 Days
|
Device success, defined as the successful creation of the fenestration(s) and successful delivery of the stent(s) at the intended target position(s).
|
0 Days
|
Procedural success
Time Frame: 1 Days
|
Procedural success, defined as no occurrence of device-related or procedure-related SAEs during the hospital stay.
|
1 Days
|
CAT
Time Frame: 12 Months
|
Improvement of the COPD Assessment Test (CAT) score from baseline.
|
12 Months
|
FEV1
Time Frame: 12 Months
|
Improvement in forced expiratory volume in 1 second (FEV1) from baseline
|
12 Months
|
Residual Volume
Time Frame: 12 Months
|
Decrease in the Residual Volume (RV) from baseline
|
12 Months
|
6MWT
Time Frame: 12 Months
|
Improvement in the 6-minute walk test from baseline
|
12 Months
|
Dyspnea scale
Time Frame: 12 Months
|
Improvement in the mMRC dyspnea scale from baseline
|
12 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 26, 2024
Primary Completion (Estimated)
June 1, 2025
Study Completion (Estimated)
June 1, 2026
Study Registration Dates
First Submitted
November 15, 2023
First Submitted That Met QC Criteria
February 7, 2024
First Posted (Actual)
February 8, 2024
Study Record Updates
Last Update Posted (Actual)
February 8, 2024
Last Update Submitted That Met QC Criteria
February 7, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL2001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Emphysema or COPD
-
University of Massachusetts, WorcesterUMass Memorial HealthEnrolling by invitation
-
Pulmonx CorporationActive, not recruiting
-
University Medical Center GroningenRecruitingEmphysema or COPDNetherlands
-
University Medical Center GroningenCompletedEmphysema or COPDNetherlands
-
University of Colorado, DenverNational Jewish HealthUnknownRespiratory Failure | COPD | COPD Exacerbation | Emphysema or COPD | COPD Exacerbation Acute | Ventilatory FailureUnited States
-
Pulmonx CorporationRecruitingEmphysema or COPD | Emphysema, PulmonarySpain, Germany, Italy, Australia
-
Universität Duisburg-EssenRecruiting
-
University Medical Center GroningenWithdrawnEmphysema or COPD
-
Uptake Medical Technology, Inc.MedPass InternationalCompleted
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)RecruitingEmphysema | COPD | Emphysema or COPDUnited States
Clinical Trials on Airway Bypass
-
Puerta de Hierro University HospitalActive, not recruitingPostoperative Complications | Weight Loss | Morbid ObesitySpain
-
Medical University of ViennaUnknown
-
Slotervaart HospitalAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)UnknownType 2 Diabetes Mellitus | Obesity, MorbidNetherlands
-
Kasr El Aini HospitalCompletedFiberoptic Tracheal Intubation
-
Nemocnice Břeclav, p.o.UnknownDiabetes Mellitus, Type 2 | Obesity, SevereCzech Republic
-
Puerta de Hierro University HospitalEnrolling by invitationPostoperative Complications | Weight Loss | Morbid ObesitySpain
-
Assistance Publique - Hôpitaux de ParisCompleted
-
PQ Bypass, Inc.UnknownPeripheral Arterial DiseaseItaly, Chile, Germany, Latvia, New Zealand, Poland
-
University of LeicesterGuy's and St Thomas' NHS Foundation Trust; Sheffield Teaching Hospitals NHS... and other collaboratorsNot yet recruitingCardiovascular Diseases | Ischemic Heart Disease | Valvular Heart Disease | Surgery-Complications
-
Cairo UniversityCompletedEndotracheal Intubation